在接受抗病毒治疗的慢性乙型肝炎患者中,功能长度变化
Hyeyeon Hong1, Minjoo Cho2, Chaeyeon Lim1
1Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Alimentary pharmacology & therapeutics
|November 27, 2023
概括
慢性乙型肝炎 (CHB) 的核类相应物 (NUC) 增加脏疾病的风险,特别是特诺福维尔二醇酸 (TDF). 恩特卡维尔和特诺福维尔阿拉芬胺 (TAF) 显示出与没有NUCs相比的安全性.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 肝病学 肝病学是一种肝病学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性乙型肝炎 (CHB) 患者服用核胺类类似物 (NUCs) 可能会出现衰退.
- 关于NUCs对功能影响的数据存在矛盾.
研究的目的:
- 根据NUC治疗类型,评估CHB患者的纵向功能变化.
- 为了比较NUC治疗的患者与未经治疗的个人关于慢性病 (CKD) 进展.
主要方法:
- 从2014年到2022年,对10,642名CHB患者进行了回顾性分析.
- 主要结局:CKD进展 (≥1阶段升高).
- 倾向性得分 (PS) 匹配用于队列比较.
主要成果:
- 在与PS匹配的队列 (1996对) 中,接受NUC治疗的患者患有较高的CKD进展风险 (7.6/100 PYs) 与未接受治疗 (4.4/100 PYs;HR=1.70).
- 诺福维尔双醇烟酸 (TDF) 组的CKD风险增加 (7.9/100 PYs) 与未接受治疗 (4.5/100 PYs; p<0.001) 相比.
- 恩特卡维尔和特诺福维尔阿拉芬胺 (TAF) 组的CKD风险与未接受治疗的患者相比相当 (分别为p=0.132和p=0.120).
结论:
- 在CHB患者中,NUC治疗,特别是TDF,与CKD进展风险增加有关.
- 恩特卡维尔和TAF表现出与没有NUC治疗相似的安全性.
- 在恩特卡维尔和TAF之间没有观察到CKD进展风险的显著差异.
相关概念视频
Renal Failure: Dose Adjustments
95
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
95
Factors Affecting Renal Clearance: Renal Impairment
99
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
99
Retrovirus Life Cycles
46.0K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
46.0K
Hepatic Drug Excretion: Enterohepatic Cycling
1.5K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
1.5K
Factors Affecting Renal Clearance: Drug's Physicochemical Properties and Plasma Levels
238
Renal clearance of a drug is influenced by various factors, including its physicochemical properties and plasma levels. These factors play a significant role in determining how efficiently the kidneys eliminate a drug.
One important factor is the drug's molecular size. The kidneys readily excrete smaller molecules below 300 Daltons (Da). On the other hand, molecules weighing between 300 and 500 Da are excreted through both urine and bile. Larger molecules above 500 Da tend to be excreted...
One important factor is the drug's molecular size. The kidneys readily excrete smaller molecules below 300 Daltons (Da). On the other hand, molecules weighing between 300 and 500 Da are excreted through both urine and bile. Larger molecules above 500 Da tend to be excreted...
238
Hepatic Drug Clearance: Effect of Protein Binding
210
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
210


